The risk-of-progression period based on the DeepSurv model can provide personalized predictions of therapeutic outcomes after EGFR-TKI treatment in a more intuitive manner and may help personalize treatment strategies for advanced NSCLC patients who have received EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.